Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis

Ursula McGivern; Darren M Mitchell; Cliona McDowell; Jolyne O'Hare; Gemma Corey; Joe M O'Sullivan

doi:10.1016/j.clgc.2012.04.003

Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis

Ursula McGivern
, Darren M Mitchell
, Cliona McDowell
, Jolyne O'Hare
, Gemma Corey
, Joe M O'Sullivan

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

The purpose of this study was to compare the prostate-specific antigen (PSA) response to either neoadjuvant bicalutamide (BC) monotherapy or neoadjuvant luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy and the subsequent effect on biochemical failure-free survival (BFFS) in men receiving radical radiotherapy (RT) for localized prostate cancer.

Original language	English
Pages (from-to)	190-5
Number of pages	6
Journal	Clinical genitourinary cancer
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/j.clgc.2012.04.003
Publication status	Published - Sept 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.clgc.2012.04.003

Cite this

McGivern, U., Mitchell, D. M., McDowell, C., O'Hare, J., Corey, G., & O'Sullivan, J. M. (2012). Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis. Clinical genitourinary cancer, 10(3), 190-5. https://doi.org/10.1016/j.clgc.2012.04.003

@article{6b83cc6437f640b7ae95d6dbeaa0b61d,

title = "Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis",

abstract = "The purpose of this study was to compare the prostate-specific antigen (PSA) response to either neoadjuvant bicalutamide (BC) monotherapy or neoadjuvant luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy and the subsequent effect on biochemical failure-free survival (BFFS) in men receiving radical radiotherapy (RT) for localized prostate cancer.",

author = "Ursula McGivern and Mitchell, \{Darren M\} and Cliona McDowell and Jolyne O'Hare and Gemma Corey and O'Sullivan, \{Joe M\}",

year = "2012",

month = sep,

doi = "10.1016/j.clgc.2012.04.003",

language = "English",

volume = "10",

pages = "190--5",

journal = "Clinical genitourinary cancer",

issn = "1938-0682",

publisher = "Elsevier Inc.",

number = "3",

}

McGivern, U, Mitchell, DM, McDowell, C, O'Hare, J, Corey, G & O'Sullivan, JM 2012, 'Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis', Clinical genitourinary cancer, vol. 10, no. 3, pp. 190-5. https://doi.org/10.1016/j.clgc.2012.04.003

Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis. / McGivern, Ursula; Mitchell, Darren M; McDowell, Cliona et al.
In: Clinical genitourinary cancer, Vol. 10, No. 3, 09.2012, p. 190-5.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Neoadjuvant hormone therapy for radical prostate radiotherapy

T2 - bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis

AU - McGivern, Ursula

AU - Mitchell, Darren M

AU - McDowell, Cliona

AU - O'Hare, Jolyne

AU - Corey, Gemma

AU - O'Sullivan, Joe M

PY - 2012/9

Y1 - 2012/9

N2 - The purpose of this study was to compare the prostate-specific antigen (PSA) response to either neoadjuvant bicalutamide (BC) monotherapy or neoadjuvant luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy and the subsequent effect on biochemical failure-free survival (BFFS) in men receiving radical radiotherapy (RT) for localized prostate cancer.

AB - The purpose of this study was to compare the prostate-specific antigen (PSA) response to either neoadjuvant bicalutamide (BC) monotherapy or neoadjuvant luteinizing hormone-releasing hormone agonist (LHRHa) monotherapy and the subsequent effect on biochemical failure-free survival (BFFS) in men receiving radical radiotherapy (RT) for localized prostate cancer.

U2 - 10.1016/j.clgc.2012.04.003

DO - 10.1016/j.clgc.2012.04.003

M3 - Article

C2 - 22677511

SN - 1938-0682

VL - 10

SP - 190

EP - 195

JO - Clinical genitourinary cancer

JF - Clinical genitourinary cancer

IS - 3

ER -

Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this